Roche (SIX: RO, ROG; OTCQX: RHHBY) and Panasonic Healthcare have allied for a new medical testing solution to combine early diagnosis and control of blood lipid and average glucose concentration (HbA1c) levels. The new designed system will pioneer with a unique approach, as it enables healthcare professionals to early detect metabolic syndrome and to improve overall therapy guidance for patients with diabetes at the point of care.
Roche’s Elecsys® Troponin T assay helps to predict mortality following noncardiac surgery
New results from the VISION Study show short-term risk assessment of cardiac events
Monitoring postoperative troponin T measurements can enhance risk stratification after noncardiac surgery and help physicians identify which patients will require more intensive monitoring and management. The large international Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION) Study by the McMaster University has shown the Elecsys Troponin T assay from Roche to improve prediction of 30-day mortality in patients following noncardiac surgery. Now published in The Journal of the American Medical Association (JAMA), these findings will help health professionals to assess the short-term risk to individual patients and tailor their monitoring, treatment and management accordingly to reduce the post-operative mortality risk.